NCT06725368
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06725368
Title Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (CARPACCIO)
Acronym CARPACCIO
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Centre Paul Strauss
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.